<rss version="2.0">
<channel>
<title>MindBranch: Pharmaceutical</title>
<description>Pharmaceutical market research products provide analysis of the latest trends, developments and market data for this industry.  Research information will help you make informed business decisions.</description>
<link>http://www.mindbranch.com/catalog/find.jsp?cat=ph</link>
<item>
<title>United States Type 2 Diabetes Market</title>
<link>http://www.mindbranch.com/products/R3740-1.html</link>
<description> <![CDATA[Intellent's new industry report focuses on the US type 2 diabetes market. This report provides valuable insight and access to the competitive information and analysis necessary to make decisions regarding the direction of the market from 2009 -2013. This primary research report features information and analysis that can't be found anywhere else. Our report features information gathered from pharmaceutical, payer, and key opinion leader interviews. This report reveals what changes lay ahead for the diabetes market in the US. It evaluates current drugs and makes projections on drugs poised to influence the future market.
  
Diabetes is one of the most common diseases in the United States, affecting more than 24 million people. It is a metabolic disorder mainly caused by a defect in insulin production or absorption, resulting in a high level of blood glucose or blood sugar. A person having blood glucose level HbA1c of greater than seven ]]></description>
<pubDate>Sat, 14 Nov 2009 00:00:00 EST</pubDate>
</item>
<item>
<title>Snapshots US Nasal Products 2009</title>
<link>http://www.mindbranch.com/products/R512-12328.html</link>
<description> <![CDATA[Snapdata's Snapshots US Nasal Products 2009 provides 2008 year-end market size data, with 2009 estimates, 5 years of historical data and five-year forecasts. The Snapshots report gives an instant overview of the US nasal product market and covers sprays, drops and inhalers, strips and nasal aspirators. Market value is based on grocery and pharmacy sales. The data is supplied in both graphical and tabular format for ease of interpretation and analysis. The Snapshots US Nasal Products 2009 forms part of Snapdata's Pharmaceuticals industry ]]></description>
<pubDate>Thu, 12 Nov 2009 00:00:00 EST</pubDate>
</item>
<item>
<title>Snapshots Denmark OTC Pharmaceuticals 2009</title>
<link>http://www.mindbranch.com/products/R512-12329.html</link>
<description> <![CDATA[Snapdata's Snapshots Denmark OTC Pharmaceuticals 2009 provides 2008 year-end market size data, with 2009 estimates, 5 years of historical data and five-year forecasts. The Snapshots report gives an instant overview of the Danish OTC pharmaceutical market and covers the total consumption of OTC medicine in Denmark divided into therapeutic groups, measured in wholesale prices, Danish Kroner (DKK) 1,000. Market Value is based on consumption in wholesale prices. The data is supplied in both graphical and tabular format for ease of interpretation and analysis. The Snapshots Denmark OTC Pharmaceuticals 2009 forms part of Snapdata's Pharmaceuticals industry ]]></description>
<pubDate>Thu, 12 Nov 2009 00:00:00 EST</pubDate>
</item>
<item>
<title>Snapshots US Pharmaceuticals 2009</title>
<link>http://www.mindbranch.com/products/R512-12335.html</link>
<description> <![CDATA[Snapdata's Snapshots US Pharmaceuticals 2009 provides 2008 year-end market size data, with 2009 estimates, 5 years of historical data and five-year forecasts. The Snapshots report gives an instant overview of the US pharmaceutical market and covers Prescription and OTC Pharmaceuticals. Market value is based on sales. The data is supplied in both graphical and tabular format for ease of interpretation and analysis. The Snapshots US Pharmaceuticals 2009 forms part of Snapdata's Pharmaceuticals industry ]]></description>
<pubDate>Thu, 12 Nov 2009 00:00:00 EST</pubDate>
</item>
<item>
<title>Snapshots Spain Pharmaceuticals 2009</title>
<link>http://www.mindbranch.com/products/R512-12334.html</link>
<description> <![CDATA[Snapdata's Snapshots Spain Pharmaceuticals 2009 provides 2008 year-end market size data, with 2009 estimates, 5 years of historical data and five-year forecasts. The Snapshots report gives an instant overview of the Spanish pharmaceutical market and covers prescription and non-prescription (OTC) pharmaceuticals.  Market value and volume is based on sales. The data is supplied in both graphical and tabular format for ease of interpretation and analysis. The Snapshots Spain Pharmaceuticals 2009 forms part of Snapdata's Pharmaceuticals industry ]]></description>
<pubDate>Thu, 12 Nov 2009 00:00:00 EST</pubDate>
</item>
<item>
<title>Snapshots South Africa Pharmaceuticals 2009</title>
<link>http://www.mindbranch.com/products/R512-12333.html</link>
<description> <![CDATA[Snapdata's Snapshots South Africa Pharmaceuticals 2009 provides 2008 year-end market size data, with 2009 estimates, 5 years of historical data and five-year forecasts. The Snapshots report gives an instant overview of the South African pharmaceutical market and covers prescription and OTC drugs. Market Value is based on total domestic sales. The data is supplied in both graphical and tabular format for ease of interpretation and analysis. The Snapshots South Africa Pharmaceuticals 2009 forms part of Snapdata's Pharmaceuticals industry ]]></description>
<pubDate>Thu, 12 Nov 2009 00:00:00 EST</pubDate>
</item>
<item>
<title>Snapshots Poland Pharmaceuticals 2009</title>
<link>http://www.mindbranch.com/products/R512-12332.html</link>
<description> <![CDATA[Snapdata's Snapshots Poland Pharmaceuticals 2009 provides 2008 year-end market size data, with 2009 estimates, 5 years of historical data and five-year forecasts. The Snapshots report gives an instant overview of the Polish pharmaceutical market and covers prescription pharmaceuticals and OTC pharmaceuticals. Market size is based on sales. The data is supplied in both graphical and tabular format for ease of interpretation and analysis. The Snapshots Poland Pharmaceuticals 2009 forms part of Snapdata's Pharmaceuticals industry ]]></description>
<pubDate>Thu, 12 Nov 2009 00:00:00 EST</pubDate>
</item>
<item>
<title>Snapshots Hungary Pharmaceuticals 2009</title>
<link>http://www.mindbranch.com/products/R512-12331.html</link>
<description> <![CDATA[Snapdata's Snapshots Hungary Pharmaceuticals 2009 provides 2008 year-end market size data, with 2009 estimates, 5 years of historical data and five-year forecasts. The Snapshots report gives an instant overview of the Hungarian pharmaceutical market and covers prescription and OTC pharmaceuticals. Market value is based on sales. The data is supplied in both graphical and tabular format for ease of interpretation and analysis. The Snapshots Hungary Pharmaceuticals 2009 forms part of Snapdata's Pharmaceuticals industry ]]></description>
<pubDate>Thu, 12 Nov 2009 00:00:00 EST</pubDate>
</item>
<item>
<title>Snapshots Venezuela Pharmaceuticals 2009</title>
<link>http://www.mindbranch.com/products/R512-12336.html</link>
<description> <![CDATA[Snapdata's Snapshots Venezuela Pharmaceuticals 2009 provides 2008 year-end market size data, with 2009 estimates, 5 years of historical data and five-year forecasts. The Snapshots report gives an instant overview of the Venezuelan pharmaceutical market and covers prescription medication and OTC pharmaceuticals. Market size is based on retail sales. The data is supplied in both graphical and tabular format for ease of interpretation and analysis. The Snapshots Venezuela Pharmaceuticals 2009 forms part of Snapdata's Pharmaceuticals industry ]]></description>
<pubDate>Thu, 12 Nov 2009 00:00:00 EST</pubDate>
</item>
<item>
<title>Snapshots US OTC Pharmaceuticals 2009</title>
<link>http://www.mindbranch.com/products/R512-12330.html</link>
<description> <![CDATA[Snapdata's Snapshots US OTC Pharmaceuticals 2009 provides 2008 year-end market size data, with 2009 estimates, 5 years of historical data and five-year forecasts. The Snapshots report gives an instant overview of the US OTC pharmaceutical market and covers non-prescription cough remedies, indigestion remedies, analgesics, vitamins, cold tablets/allergy/sinus, nasal remedies, ear drops/treatments and others. Market value is based on chemistsâ&#128;&trade; sales at manufacturersâ&#128;&trade; prices. The data is supplied in both graphical and tabular format for ease of interpretation and analysis. The Snapshots US OTC Pharmaceuticals 2009 forms part of Snapdata's Pharmaceuticals industry ]]></description>
<pubDate>Thu, 12 Nov 2009 00:00:00 EST</pubDate>
</item>
<item>
<title>Merck &amp; Co. Performance, Products, Pipeline and Potential</title>
<link>http://www.mindbranch.com/products/R16-23326.html</link>
<description> <![CDATA[Pharmaceutical company intelligence reports from Espicom provide a full review of the company's activities together with five-year sales forecasts for its key products. The company's financial performance is covered in-depth, from its latest results to a complete analysis of its latest full fiscal year and an outlook for the future. A section on company strategy covers mergers, acquisitions and divestitures, key agreements, products and R&D.  An overview of key products and R&D is followed by a comprehensive review of the company's product portfolio and research and development pipeline by therapeutic area. In addition, supplementary appendices provide more in-depth information on financials, agreements and corporate events.
]]></description>
<pubDate>Tue, 10 Nov 2009 00:00:00 EST</pubDate>
</item>
<item>
<title>Nigeria Pharmaceuticals and Healthcare Report Q1 2010</title>
<link>http://www.mindbranch.com/products/R302-8740.html</link>
<description> <![CDATA[The value of Nigeria&rsquo;s pharmaceutical market in 2008 was NGN80.9bn (US$680mn). We forecast a12.8% year-on-year (y-o-y) growth in local currency during 2009, expecting that the market will grow bya compound annual growth rate (CAGR) of 10.19% over our five-year forecast period (2009-2014), toreach NGN148.2bn (US$1.2bn). At the same time, expenditure on medicines as a percentage of GDP willcontinue to hover around a minor 0.3%, illustrative of the emerging status of the market and thewidespread lack of access to and financing for necessary medicines. In fact, Nigeria is viewed as thethird-least promising market in the Middle East and Africa (MEA) region, as ranked by BMI&rsquo;s Q110Pharmaceutical Business Environment Ratings (BER) that assess the 17 key countries.  Moreover, Nigeria continues to battle trade in counterfeit medicines. In August 2009, Nigerian authoritiesproposed a new strategy for the reduction of counterfeiting in the country. In addition to placing emphasison only allowing accredited and qualified personnel ]]></description>
<pubDate>Tue, 10 Nov 2009 00:00:00 EST</pubDate>
</item>
<item>
<title>Company Financials: Bayer AG</title>
<link>http://www.mindbranch.com/products/R313-57885.html</link>
<description> <![CDATA[ Introduction   The Company Financials offers insights into the financial performance of the company over last five years for about 1000 leading global companies. The datapack covers wealth of financial information relating to income statement, balance sheet, and cash flow statements.    Scope   Contains five years data on income statement, balance sheet, cash flows and other financials in the reported currency and its US Dollar translation  Provides key ratios  Includes information on revenue distribution by business segments and geographies   Highlights   Bayer is a German chemical and pharmaceutical group. It operates in Asia Pacific, Europe, North America, Latin America, Africa, and Middle East.   Reasons to Purchase   Access important financial information and analysis on the company in a single datapack  Understand the financial evolution of the company over the last five years  Build the periodic assessment of the company's performance for five year adjusted financial data along with key ratios and market capitalization   Please note:   this is delivered as a Zip ]]></description>
<pubDate>Tue, 10 Nov 2009 00:00:00 EST</pubDate>
</item>
<item>
<title>Argentina Pharmaceuticals and Healthcare Report Q1 2010</title>
<link>http://www.mindbranch.com/products/R302-8735.html</link>
<description> <![CDATA[The value of Argentina&rsquo;s pharmaceutical market in 2008 was US$3.7bn. BMI&rsquo;s updated forecasts see themarket reaching a value of US$6.12bn by 2014, representing a compound annual growth rate (CAGR) of12.68% in US dollar terms. With Argentina&rsquo;s economy bouncing back after the economic crisis at thebeginning of the decade, we expect the total value of the drug market to reach US$9.3bn by 2019.  However, the deep global recession has had a short-term impact on drug expenditure in Argentina, as outof-pocket spending and government finances were hit, and the Argentine peso was devalued. Indeed, in2009 we forecast that the drug sector will shrink by 10% in US dollar terms before recovering in 2010.  However, the long-term fundamentals of the market remain strong, and in BMI&rsquo;s opinion Argentina isone of the most promising pharmaceutical markets in Latin America in terms of growth prospects.  Despite the economic downturn, Argentina&rsquo;s government has promised to continue to invest heavily ]]></description>
<pubDate>Tue, 10 Nov 2009 00:00:00 EST</pubDate>
</item>
<item>
<title>Poland Pharmaceuticals and Healthcare Report Q1 2010</title>
<link>http://www.mindbranch.com/products/R302-8729.html</link>
<description> <![CDATA[Poland is one of the highest value markets in Central and Eastern Europe (CEE) and as a result is adestination for almost all multinationals operating within the region. Poland&rsquo;s pharmaceutical market hasshown consistently strong growth during 2009, despite economic pressures. Over the next 10 years BMIforecasts that pharmaceutical sales will record a compound annual growth rate (CAGR) of 7.9% in USdollar terms, highlighting its potential for foreign investors.  Poland, however, does have a number of drawbacks which make it less than perfect, particularly for BigPharma. In BMI&rsquo;s Q110 Business Environment Ratings, Poland places sixth out of the 20 CEE marketsin our coverage universe. While scoring relatively well in both pharmaceutical market and country riskcategories, demographic and market risk factors constrain a table-topping score. One of the majorfrustrations for multinationals is delays in reimbursement for innovative products and a strong preferencefor the domestic industry.  Budgeted spending on healthcare by the National Health Fund ]]></description>
<pubDate>Tue, 10 Nov 2009 00:00:00 EST</pubDate>
</item>
<item>
<title>Thailand Pharmaceuticals and Healthcare Report Q1 2010</title>
<link>http://www.mindbranch.com/products/R302-8718.html</link>
<description> <![CDATA[In BMI&rsquo;s Pharmaceutical Environment Ratings (BER) table for Q110, Thailand slipped from ninth totenth position among the 15 key markets surveyed in the Asia Pacific region. Thailand&rsquo;s growing andageing population represents a substantial commercial opportunity for drugmakers, although itscontroversial compulsory licensing scheme is deterring foreign investment, as is its political instability.Additionally, the local operating environment is considered to be negative from the point of view offoreign research-based companies, due to a lack of data exclusivity, rife counterfeiting and parallelimportation, compounded by the introduction of health economics in the approval of patented drugs.  However, prospects for patent law reform are improving, as a result of Thailand&rsquo;s involvement in regionalharmonisation initiative and the resumption of talks with the US over a free trade agreement (FTA).  Nevertheless - and despite the currently low per capita spending on medicines - Thailand&rsquo;spharmaceutical market is expected to perform better than most of its regional peers, as global economicdownturn ]]></description>
<pubDate>Tue, 10 Nov 2009 00:00:00 EST</pubDate>
</item>
<item>
<title>Australia Pharmaceuticals and Healthcare Report Q1 2010</title>
<link>http://www.mindbranch.com/products/R302-8717.html</link>
<description> <![CDATA[Australia&rsquo;s pharmaceutical market is among the most developed in the Asia-Pacific region. Access tomedication is good across all sections of the population, with per-capita spending calculated at US$352 in2008. While not particularly high by Western European or North American standards, it represents thesecond highest level in the region, behind only Japan. Over the next 10 years BMI forecasts that spendingon pharmaceuticals - including all prescription and over-the-counter (OTC) medicines - will increase at acompound annual growth rate (CAGR) of 3.1%, representing modest, if not overly impressiveperformance.  The Asia Pacific region&rsquo;s attractiveness to research-based multinational drugmakers has increased,according to BMI&rsquo;s Pharmaceuticals Business Environment Ratings for Q110. Australia has maintainedits premier ranking in the Business Environment Ratings for the Asia Pacific region in Q110. Australia&rsquo;sposition, ahead of the far higher value market of Japan, reflects more positive growth dynamics and morefavourable general market conditions.  Australia&rsquo;s population will expand steadily over the next decade, driven ]]></description>
<pubDate>Tue, 10 Nov 2009 00:00:00 EST</pubDate>
</item>
<item>
<title>Kenya Pharmaceuticals and Healthcare Report Q1 2010</title>
<link>http://www.mindbranch.com/products/R302-8739.html</link>
<description> <![CDATA[BMI&rsquo;s proprietary Drug Expenditure Forecast Model reveals that the Kenyan pharmaceutical market willreturn to a double-digit growth rate in 2009 (in local currency terms), after declining to single-digitgrowth the previous year. During 2008, OTC and prescription medicine sales reached KES17.7bn(US$0.229bn), up from KES14.4bn (US$0.215bn) in 2007. This represented a 9.6% growth in localcurrency terms and a 6.7% growth in US dollar terms, down from the 13.2% and 21.5% growth ratesachieved during 2007. By 2014, BMI believes that the Kenyan drug market will reach a value ofKES33.48bn (US$0.650bn), equating to a compound annual growth rate (CAGR) of 13.53% in localcurrency terms and 22.8% in US dollar terms. By 2019, BMI expects the pharmaceutical market to havereached a value of KES57.2bn (US$1.49bn), a 2009-2019 CAGR of 26.35% in Kenyan shilling terms anda staggering 45.0% in US dollar terms.  In BMI&rsquo;s Business Environment Ratings for Q110, despite Kenya&rsquo;s overall pharmaceutical ratingimproving marginally to reach ]]></description>
<pubDate>Tue, 10 Nov 2009 00:00:00 EST</pubDate>
</item>
<item>
<title>Takeda Pipeline, Products, Performance, Potential</title>
<link>http://www.mindbranch.com/products/R16-23327.html</link>
<description> <![CDATA[Pharmaceutical company intelligence reports from Espicom provide a full review of the company's activities together with five-year sales forecasts for its key products. The company's financial performance is covered in-depth, from its latest results to a complete analysis of its latest full fiscal year and an outlook for the future. A section on company strategy covers mergers, acquisitions and divestitures, key agreements, products and R&D.  An overview of key products and R&D is followed by a comprehensive review of the company's product portfolio and research and development pipeline by therapeutic area. In addition, supplementary appendices provide more in-depth information on financials, agreements and corporate events.
]]></description>
<pubDate>Tue, 10 Nov 2009 00:00:00 EST</pubDate>
</item>
<item>
<title>Drug Price/Cost Debate: Coping with Escalating Pricing Pressures</title>
<link>http://www.mindbranch.com/products/R55-681.html</link>
<description> <![CDATA[ Introduction   
Insinuations of profi teering were made against an H1N1 swine flu vaccine manufacturer in the summer of 2009.
As the swine flu epidemic began to take on serious proportions, public scrutiny in the United Kingdom focused
on manufacturers developing vaccines for the prevention of this disease and on what constitutes a fair price
for a drug. The U.K. public&rsquo;s suspicion of pharmaceutical profi teering in the H1N1 vaccine arena is just the tip
of the iceberg in the ongoing and acrimonious battle over the prices that pharmaceutical companies charge for
drugs and the costs that payers must cover to meet the increasing demands for healthcare. With global economies
in the tank owing to the ongoing worldwide recession, the pitch of the battle increased in 2009. Some
companies are developing new strategies to combat increased price/cost pressures. Who has been successful,
and who has not? What strategies are in play, ]]></description>
<pubDate>Mon, 09 Nov 2009 00:00:00 EST</pubDate>
</item>
<item>
<title>Company Financials: Chattem, Inc.</title>
<link>http://www.mindbranch.com/products/R313-57904.html</link>
<description> <![CDATA[ Introduction   The Company Financials offers insights into the financial performance of the company over last five years for about 1000 leading global companies. The datapack covers wealth of financial information relating to income statement, balance sheet, and cash flow statements.    Scope   Contains five years data on income statement, balance sheet, cash flows and other financials in the reported currency and its US Dollar translation  Provides key ratios  Includes information on revenue distribution by business segments and geographies   Highlights   Chattem is a manufacturer and marketer of branded over-the-counter (OTC) healthcare products, toiletries and dietary supplements. The company primarily operates in the US. It is headquartered in Chattanooga, Tennessee and employs about 512 people.   Reasons to Purchase   Access important financial information and analysis on the company in a single datapack  Understand the financial evolution of the company over the last five years  Build the periodic assessment of the company's performance for five year adjusted financial data along with key ratios and market ]]></description>
<pubDate>Mon, 09 Nov 2009 00:00:00 EST</pubDate>
</item>
<item>
<title>Profiting From Consumer Mega-Trends in Asia Pacific: Health</title>
<link>http://www.mindbranch.com/products/R313-57629.html</link>
<description> <![CDATA[ Introduction   For three-quarters of Asia Pacific consumers,  maintaining or improving health  has become more important to them personally over the last two years.     This report outlines how over 40 health-driven trends influence consumer lifestyles and product choices and considers the implications and opportunities for industry players   Scope   Detailed analysis outlining what constitutes 'value' for Asia Pacific consumers (trends are, after all, a reflection of what's important to consumers)  Offers Asia Pacific sector insights, benchmarked against global sentiment, to cater for contextualized regional specific information needs  Covers all major FMCG sectors, but also with applicability to wider consumer goods audiences  Part of Datamonitor's mega-trend report series which outline the most important issues shaping current and future buying behavior   Highlights   Good trend-watching is about taking the bigger-picture approach. Adopting a broader perspective to trend-tracking facilitates better decision making by overcoming 'category myopia'. Monitoring the broader FMCG environment will enable bigger picture learning that can be applied ]]></description>
<pubDate>Mon, 09 Nov 2009 00:00:00 EST</pubDate>
</item>
<item>
<title>Chiropractor Offices</title>
<link>http://www.mindbranch.com/products/R3470-3241.html</link>
<description> <![CDATA[The US chiropractic industry includes about 36,000 businesses and 60,000 licensed chiropractors with combined annual revenue of nearly $10 billion. No major companies dominate. The industry is highly fragmented: the top 50 chiropractor offices generate less than 10 percent of revenue.   COMPETITIVE LANDSCAPE  Demand for chiropractic services is driven by the aging US population and the overall acceptance of alternative medicine and chiropractic care. The profitability of individual companies depends on effective marketing and maximizing billable hours. Large companies have advantages in regional name recognition. Small companies can compete effectively by serving a small community or integrating the practice into a larger holistic health practice. The industry is labor-intensive: annual revenue per worker is about $80,000.   Chiropractors compete with physical therapists and medical doctors, many of whom consider chiropractic treatments ineffective.   PRODUCTS, OPERATIONS & TECHNOLOGY  A chiropractor's major service is treating patients who have pain due to muscular or skeletal injuries. Patient ]]></description>
<pubDate>Mon, 09 Nov 2009 00:00:00 EST</pubDate>
</item>
<item>
<title>Prostate Cancer Drug Discoveries: What the Future Holds</title>
<link>http://www.mindbranch.com/products/R16-23325.html</link>
<description> <![CDATA[ Prostate cancer is the second leading cause of cancer in the US and the third most common cancer worldwide. More than two million men in the US suffer with prostate cancer. Find out more about market developments in this chapter of Cancer Drug Discoveries.
]]></description>
<pubDate>Thu, 05 Nov 2009 00:00:00 EST</pubDate>
</item>
<item>
<title>Les Laboratoires Servier: PharmaVitae Profile</title>
<link>http://www.mindbranch.com/products/R313-57676.html</link>
<description> <![CDATA[ Introduction   This analysis examines the historical and forecast performance for Servier in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.   Reasons to Purchase   Benchmark Servier's performance against key rivals in the prescription pharmaceutical sector  Assess the impact of the invalidation of Coversyl's key formulation patents in July 2007 on Servier's forecast revenue performance  Consider Servier's growth opportunities over 200814; the launch of Valdoxan,  expansion of generics subsidiary Biogaran, and growth in RoW markets   Please note:   this is delivered as a Zip ]]></description>
<pubDate>Wed, 04 Nov 2009 00:00:00 EST</pubDate>
</item>
</channel>
</rss>
